Amylyx Pharmaceuticals, Inc.
AMLX evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $3.61B
- Lead Asset:
- AMX0035 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for AMLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMLX
Amylyx Pharmaceuticals (AMLX) is a clinical-stage biotech developing therapies for neurodegenerative and metabolic diseases, with a lead candidate avexitide showing positive Phase 3 results in post-bariatric hypoglycemia.
Key risk: Cash burn and deficit
BioSniper Score
Based on 4 of 6 signals
Market Cap
$3.61B
Cash Runway
—
Lead Asset
AMX0035 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 7 clinical trials for Amylyx Pharmaceuticals, Inc..
Amylyx Pharmaceuticals (AMLX) is a clinical-stage biotech developing therapies for neurodegenerative and metabolic diseases, with a lead candidate avexitide showing positive Phase 3 results in post-bariatric hypoglycemia.
- Cash & equivalents of $49.3M as of 2026-06-30 [sec].
- Phase 3 LUCIDITY trial of avexitide for PBH met primary and all secondary endpoints, supporting a planned NDA filing [news].
- Phase 1 LUMINA trial of AMX0114 for ALS showed no drug-related serious adverse events in Cohort 1; biomarker data presented June 2026 [sec_mda · as of 2026-08-06].
- Accumulated deficit of $836.1M as of 2026-06-30 [sec_mda · as of 2026-08-06].
- Cash runway estimated into 2028 based on existing resources as of June 30, 2026 [sec_mda · as of 2026-08-06].
What works
- Avexitide Phase 3 success in PBH, a condition with no approved therapies, supports a clear regulatory path [news].
- AMX0114 Phase 1 data show tolerability and no serious adverse events, enabling dose escalation [sec_mda · as of 2026-08-06].
- Cash runway into 2028 provides multi-year operational visibility [sec_mda · as of 2026-08-06].
What to weigh
- Net loss of $43.4M for the period ending 2026-06-30 and accumulated deficit of $836.1M indicate ongoing cash burn [sec] [sec_mda · as of 2026-08-06].
- Pipeline candidates (AMX0035, AMX0114, AMX0318) are in early or mid-stage trials with no approved products yet [sec_mda · as of 2026-08-06].
- Successful development and commercialization of all candidates is highly uncertain due to numerous risks [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Phase 3 avexitide trial met primary and all secondary endpoints
“Amylyx Pharmaceuticals (NasdaqGS: AMLX) reported overwhelmingly positive topline Phase 3 results for avexitide in post-bariatric hypoglycemia, with the trial meeting its primary and all secondary endpoints.”
News · August 19, 2026
AMX0114 Cohort 1 showed no drug-related serious adverse events
“AMX0114 showed no drug-related serious adverse events, or SAEs, and no serious nervous system disorder adverse events, or AEs, in Cohort 1 (lowest dose level 12.5 mg).”
SEC MD&A · August 6, 2026
Cash runway into 2028
“We believe our existing cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund our operations into 2028.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2023-03-03 · Phase 2 start for AMX0035 in Wolfram syndrome — A Phase II study of safety and efficacy of AMX0035 in adult patients with Wolfram syndrome.
- 2023-12-21 · Phase 2b/3 start for AMX0035 in PSP (ORION) — A Phase 2b/3 study of safety and efficacy of AMX0035 in progressive supranuclear palsy.
- 2025-04-07 · Phase 1 start for AMX0114 in ALS — Phase 1 multiple ascending dose study of AMX0114 in adult participants with ALS.
- 2025-04-29 · Phase 3 start for avexitide in PBH — Phase 3 multicenter study of avexitide in post-bariatric hypoglycemia.
Risks & what to watch (3)›
Key risks
- Cash burn and deficit — Net loss of $43.4M and accumulated deficit of $836.1M as of 2026-06-30 [sec] [sec_mda · as of 2026-08-06].
- No approved products — All pipeline candidates are in clinical trials; none have received FDA approval [sec_mda · as of 2026-08-06].
- Development uncertainty — Successful development and commercialization of all candidates is highly uncertain [sec_mda · as of 2026-08-06].
What to watch
- NDA filing for avexitide in PBH following positive Phase 3 results [news].
- Biomarker data from LUMINA Cohort 1 presented at ENCALS June 2026 [sec_mda · as of 2026-08-06].
- Progress of Phase 2 AMX0035 trial in Wolfram syndrome and wind-down of PSP trial [sec_mda · as of 2026-08-06].
- Cash runway updates as spending continues into 2028 [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Amylyx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Amylyx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.11 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
1 buy · 2 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 17.2%
- Days to cover
- 13.1
- Shares short
- 14,800,969
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals (AMLX) is a clinical-stage biotech developing therapies for neurodegenerative and metabolic diseases, with a lead candidate avexitide showing positive Phase 3 results in post-bariatric hypoglycemia.
What is Amylyx Pharmaceuticals, Inc.'s lead drug candidate?
Amylyx Pharmaceuticals, Inc.'s most advanced tracked candidate is AMX0035 (Phase 3) for Wolfram Syndrome.
Who is the CEO of Amylyx Pharmaceuticals, Inc.?
Mr. Joshua B. Cohen is the chief executive officer of Amylyx Pharmaceuticals, Inc. (AMLX).
Where is Amylyx Pharmaceuticals, Inc. headquartered?
Amylyx Pharmaceuticals, Inc. (AMLX) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Amylyx Pharmaceuticals, Inc. focus on?
Amylyx Pharmaceuticals, Inc. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.